A phase I study is now underway for an investigational, oral adrenocorticotropic hormone antagonist, CRN04894, aimed at the treatment of congenial adrenal hyperplasia and Cushing's disease, Crinetics Pharmaceuticals announced.
__________________
Г.А. Мельниченко
|